{"id":12972,"date":"2019-04-03T16:39:13","date_gmt":"2019-04-03T20:39:13","guid":{"rendered":"https:\/\/medicarereport.org\/?p=12972"},"modified":"2019-04-03T16:39:13","modified_gmt":"2019-04-03T20:39:13","slug":"faced-with-rising-anger-on-drug-prices-cigna-plans-to-reduce-insulin-costs-to-25-a-month-for-many-patients","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=12972","title":{"rendered":"Faced with rising anger on drug prices, Cigna plans to reduce insulin costs to $25 a month for many patients"},"content":{"rendered":"<p>(By Matthew Herper for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap\">R<\/span>esponding to massive public pressure about the high price of life-saving insulin for people with diabetes, the insurance giant Cigna and its drug benefit arm, Express Scripts, aim to reduce the monthly cost of insulin from $40, on average, to $25 for many patients.\u00a0 Continue reading<a href=\"https:\/\/www.statnews.com\/2019\/04\/03\/cigna-reduce-insulin-cost\/?utm_source=STAT+Newsletters&amp;utm_campaign=6e99b2139c-Pharmalot&amp;utm_medium=email&amp;utm_term=0_8cab1d7961-6e99b2139c-149624405\"> article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Matthew Herper for STAT) Responding to massive public pressure about the high price of life-saving insulin for people with<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17,21,15],"tags":[],"class_list":["post-12972","post","type-post","status-publish","format-standard","hentry","category-emerging-health-issues","category-health-care-finance","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12972"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12972\/revisions"}],"predecessor-version":[{"id":12973,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12972\/revisions\/12973"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}